Tissue-specific cancer stem/progenitor cells: Therapeutic implications

doi:10.4252/wjsc.v15.i5.323

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3396)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-1) series.

Item

Count

PDF

135

WORD

HTML

1660

Figures (1-2)

166

Tables (1-1)

179

Sum=2190

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

133

Download

459

Sum=592

Publishing Process of This Article

Item

Count

Browse

243

Download

371

Sum=614

May 26, 2023 (publication date) through Nov 23, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Stem Cells

ISSN

1948-0210

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Stem Cells. May 26, 2023; 15(5): 323-341
Published online May 26, 2023. doi: 10.4252/wjsc.v15.i5.323

Table 1 Summary of the most prominent biomarkers required to identify and isolate the tissue-specific cancer stem cells in prostate, colon, bladder, breast, and lung tumors

TSCSCs markers	PCSCs	CCSCs	BCSCs	BrCSCs	LCSCs	Ref.
CD24	-	+	+	-		[64,90,159,160]
CD26		+				[161]
CD29	+	+		+	+	[99,162-164]
CD44	+	+	+	+	+	[31,63,74,108,165]
CD47			+	+	+	[78,166,167]
CD49b (integrin α₂ or ITGA2)	+	+	-	+	+	[168-171]
CD49f (integrin α₆ or ITGA6)	+	+	+	+	+	[99,169,172,173]
CD51	+	+				[69,174]
CD61				+		[99]
CD66c		+	-			[84,175]
CD67LR			+			[84]
CD87					+	[116]
CD90		+	+	+	+	[99,110,176,177]
CD117	+			+	+	[38,116,178]
CD126		+		+	+	[179-181]
CD133	+	+	+	+	+	[28,51,87,99,107]
CD151	+					[35]
CD166	+	+		+	+	[46,104,182,183]
CD326 (EpCAM or ESA)	+	+	+	+	+	[48,56,116,184,185]
Integrin α₂β₁	+	+				[27,186]
TRA-1-60	+	+				[35,187]
Trop2	+					[45]
CXCR4	+	+		+	+	[102,162,188,189]
ABCB5		+				[73]
ABCG2	+	+	+	+	+	[49,102,177,190,191]
MAGE-A3			+			[177]
GLDC					+	[102]
ALDH	+	+	+	+	+	[44,68,96,102,177]
BCMab1			+			[79]
Lgr5		+		+	+	[53,99,192]
Prox1	+	+				[70,193]
EMA (MUC1)	+	+	-			[77,194,195]
E-cadherin	+	+				[196,197]
ZEB-1	+	+		+	+	[198-200]
PSA	-					[201]
CK5	+		+	+	+	[117,202-204]
CK17			+			[89]
CK18	-		-	-		[89,205,206]
CK20			-			[89]
Ar-v7	+					[207]

+: Over-expressed; -: Under-expressed; Blank: Not found in the literature/controversial. TSCSCs: Tissue-specific cancer stem cells; PCSCs: Prostate cancer stem cells; CCSCs: Colon cancer stem cells; BCSCs: Bladder cancer stem cells; BrCSCs: Breast cancer stem cells; LCSCs: Lung cancer stem cells; EpCAM: Epithelial cell adhesion molecule; TRA-1-60: T cell receptor alpha locus; ALDH: Aldehyde dehydrogenase; EMA: Epithelial membrane antigen.

Citation: Yehya A, Youssef J, Hachem S, Ismael J, Abou-Kheir W. Tissue-specific cancer stem/progenitor cells: Therapeutic implications. World J Stem Cells 2023; 15(5): 323-341
URL: https://www.wjgnet.com/1948-0210/full/v15/i5/323.htm
DOI: https://dx.doi.org/10.4252/wjsc.v15.i5.323